ADA Scientific Sessions - American Diabetes Association Scientific Sessions

The DPPOS is the long-term follow-up of the Diabetes Prevention Program (DPP), a multicenter trial conducted from 1996 to 2001 that established the success of either an intensive lifestyle program or treatment with metformin to prevent or delay the development of T2D in individuals who were considered at high risk for developing the disease.

Oral insulin (OI) slows insulin decline in those at high risk for type 1 diabetes (T1D), according to a poster session at the American Diabetes Association’s 80th virtual Scientific Sessions.

There have not been many evaluations of the prevalence of, and factors associated with, use of DSME/S and support programs in newly diagnosed patients with type 2 diabetes (T2D) in Louisiana, according to the study authors.

The slowed metabolic decline among the OI trial participants at highest risk was assessed and defined by the DPT1 Risk Scores over a 6.75 threshold.

The TEDDY study also aims to identify environmental triggers that cause the immune destruction of beta cells.

The results of the study demonstrated that dapagliflozin was able to reduce new-onset diabetes by 32%.

The results of the real-world, observational study were presented by Eli Lilly during the American Diabetes Association's 80th Virtual Scientific Sessions.

Dapagliflozin is typically used as a second line GLM in T2D and often added to metformin.

A study of more than 9000 people finds overall need for better access to psychological and other non-medical diabetes care for people living with diabetes and their caregivers.

Managing diabetes in rural areas is difficult due to limited access to specialty care and self-management programs.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new subgroup analysis from the phase 3 CREDENCE study,

In recent years, diabetes technology has evolved at a rapid pace.

Data from 2 studies noted no differences between either program.

Researchers did not find a statistically significant benefit in using vitamin D to decrease the likelihood of developing type 2 diabetes in high risk individuals.

Paul Burton, MD, the Vice President of Janssen Scientific Affairs, LLC, explains the role of pharmacists in diagnosing and treating diabetes with their drug, Invokana (canagliflozin).

In addition to showing no significant imbalance of BKLE amputation, the study also identified a HHF reduction in the general T2D population.

People with T2D have an increased risk of damage to the eyes, kidneys, nerves, legs, heart and brain, and many of these complications can ultimately affect mortality.

Risk factor modification remains key to managing patients with HIV and diabetes.

In this video, Priscilla Hsue, MD, from the University of California San Francisco School of Medicine, explains other health issues patietns with HIV may face as they age.

Kathryn Kreider, DNP, FNP-BC, BC-ADM, explains diabetes associations and the implications it has on health management for patients with diabetes.

Kathryn Kreider, DNP, FNP-BC, BC-ADM, from Duke University, discusses treatment options for patients with diabetes distress.

Leaders in diabetes research and treatment provide resources to overcome gendered disparities in the field.

A study of another such program—Healthy MOMs, or Mothers on the Move—has shown significant improvements in dietary practices and the incidence of depressive symptoms in Latina mothers at risk for type 2 diabetes.

The top prizes in the global Ascenia Diabetes Challenge were announced Friday at the American Diabetes Association’s 78th Annual Scientific Sessions in Orlando, Florida.

Patients with type 1 diabetes who received a generic vaccine had normal blood sugar levels 8 years later.

This weekly video program provides an inside look at our upcoming American Diabetes Association Scientific Sessions coverage.

Adults with diabetes are 2 to 4 times more likely to have cardiovascular disease, which includes heart disease, heart failure, heart attack and stroke, than people without diabetes

Tracey D. Brown will welcome 16,000 attendees to the premier diabetes health care conference in her first month as chief executive of the American Diabetes Association.

The American Diabetes Association at its 78th Scientific Sessions will recognize 4 physicians who have worked to advance diabetes research and improve patient health outcomes.

Some 13,000 health care professionals from around the world convene each year at this popular meeting to discuss case studies, sympsia, oral presentations, and other forms of new research.